Figure 8
Tumor growth in BDF-1 mice. Effects of three herbal batches on Camptosar® anti-tumor activity in mice. PHY906-6, PHY906-10 and HQT-F were tested to monitor enhancement of the activity of Camptosar® on solid colon-38 tumors in vivo. BDF-1 mice (20-22 grams) with tumor sizes of 150-300 mm3 were selected. Five mice were used in each of four groups: (1) control (PBS for intraperitoneal or water for oral), (2) PHY906 or HQT only (500 mg/kg), (3) Camptosar® (360 mg/kg) and (4) Camptosar® (360 mg/kg) and PHY906/HQT (500 mg/kg). PHY906 was given orally (po) whereas Camptosar® was administered intraperitoneally (ip). Two different animal studies were conducted. The first study compared PHY906-6 with PHY906-10 (upper panel). The results of this study indicate that both PHY906-6 and PHY906-10 enhance the anti-tumor effect of Camptosar® compared with Camptosar® alone (P = 0.0001). A second independent study compared PHY906-6 with HQT-F (lower panel). The results indicate that PHY906-6 enhances the anti-tumor effect of Camptosar® when compared with Camptosar® alone (P = 0.0001). There was no significant enhancement by the HQT-F batch (p = 0.386)